Wednesday, 13 November 2024
  
Login

Australia's most trusted
source of pharma news

Wednesday, 13 November 2024
News

Aussie needle-free RSV vax coming

Posted 29 October 2024 PM

The United States National Institutes of Health (NIH) has granted Aussie biotech Vaxxas the licence to a vaccine antigen candidate (DS2), to protect against Respiratory Syncytial Virus (RSV).

Vaxxas' worldwide licence from the NIH enables the company to develop the first needle-free, room-temperature stable RSV vaccine to enter clinical studies.

The DS2 RSV vaccine antigen candidate was developed by scientists at the NIH's Vaccine Research Centre and the National Institute of Allergy and Infectious Diseases.

"Published preclinical results show the potential immunogenic advantages of this antigen candidate as the basis for an RSV vaccine to provide robust and durable protection," Vaxxas CEO David Hoey said.

"These potential advantages, coupled with the potential of the Vaxxas needle-free technology to eliminate the need for refrigerated distribution and enable self-administration, could offer a vaccine that makes a significant impact on the way we protect populations against this serious respiratory infection in the future."

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (14)

Access & Reimbursement (1)

Clinical & Medical, R&D (8)

Regulatory, Pharmacovigilance & QA (2)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.